On this page
- 1Why IgA Nephropathy Can Only Be Diagnosed With a Kidney Biopsy
- 2What Each Letter of an IgA Nephropathy MEST-C Score Means
- 3How Urine Protein Relates to the IgA Nephropathy Outlook
- 4How IgA Nephropathy Treatment Starts Under the 2025 KDIGO Guideline
- 5Is IgA Nephropathy Inherited?
- 6Tracking IgA Nephropathy Through the First Year
- 7Common questions
- Sources
Two numbers are worth asking about at every visit, urine protein and eGFR, along with your blood pressure. The KDIGO 2025 guideline aims for urine protein under 0.5 grams a day, ideally under 0.3, and blood pressure at or below 120/70.
A kidney biopsy report for IgA nephropathy usually ends with a short code such as M1 E0 S1 T0 C0. That code sits alongside a urine protein result and an eGFR, a blood test estimate of kidney function. The 2025 KDIGO guideline uses protein and eGFR to judge risk and guide treatment.
KDIGO, the international group that writes kidney care guidelines, treats IgA nephropathy as a lifelong condition. Its 2025 guideline counts anyone whose urine protein stays at 0.5 grams a day or more as at risk of losing kidney function. It says treatment should be considered for all of them (KDIGO, 2025).
Treatment options have grown quickly. The FDA approved the first drug for IgA nephropathy in December 2021, and 7 drugs are now FDA-approved for some adults with it. Of those, 4 have accelerated approval based on lowering urine protein.
Why IgA Nephropathy Can Only Be Diagnosed With a Kidney Biopsy
Only a kidney biopsy can diagnose IgA nephropathy, because no blood or urine test has been validated to confirm it, according to the KDIGO 2025 guideline. The pathologist looks for IgA, an antibody the immune system makes. It should be the main or a co-main deposit in the glomeruli, the tiny filters that clean the blood (Roberts et al., 2009).
KDIGO now encourages doctors to consider a biopsy for adults with urine protein of 0.5 grams a day or more when IgA nephropathy is possible. Its authors call this a more liberal biopsy policy (Floege et al., 2025). The Oxford scoring findings apply to samples with at least 8 glomeruli (Trimarchi et al., 2017).
Once IgA deposits are found, doctors check for other conditions that can cause them. The KDIGO list includes infections such as HIV and hepatitis, inflammatory bowel disease, liver cirrhosis, IgA vasculitis and other autoimmune diseases. NIDDK, part of the National Institutes of Health, also lists celiac disease.
It is the most common primary glomerular disease worldwide, and the average age at diagnosis is between 30 and 40, according to KDIGO. About 1 in 10 kidney biopsies in the United States show it, according to NIDDK. Reported rates vary widely, from 0.39 to 1.4 new cases per 100,000 people a year in US studies to 4.2 in Japan (Kiryluk et al., 2023).
What Each Letter of an IgA Nephropathy MEST-C Score Means
The MEST-C score comes from the Oxford classification, a shared shorthand that lets a biopsy read in one hospital mean the same thing in another. Each letter names a kind of kidney damage, and its number says whether the pathologist saw it and how much (Trimarchi et al., 2017).
| Letter | What the pathologist looks for | Possible scores | What it has been linked to |
|---|---|---|---|
| M | Mesangial hypercellularity, extra cells in the support tissue at the center of each filter | M0 or M1, with M1 meaning more than half of the filters show it | Lower 5-year kidney survival, about 90% with M0 against under 80% with M1 in people with similar lab results |
| E | Endocapillary hypercellularity, extra cells crowding the small blood vessels inside a filter | E0 absent or E1 present | A worse outlook, but only in people who did not receive immune-suppressing treatment |
| S | Segmental sclerosis, scarring in part of a filter | S0 absent or S1 present | A worse long-term outlook |
| T | Tubular atrophy and interstitial fibrosis, lasting damage to the tubes and tissue between the filters | T0 at 25% or less, T1 at 26-50%, T2 above 50% | The most consistent single predictor of outcome, largely reflecting how far the disease had gone by the biopsy |
| C | Crescents, crescent-shaped clusters of cells inside a filter that signal active inflammation | C0 none, C1 in at least 1 filter, C2 in more than 25% of filters | C1 points to risk if immune-suppressing treatment is not given, and C2 points to risk even with it |
Pathologists do not always score the same slide the same way. In the 2016 Oxford update, hospital pathologists scored M1 twice as often as the study's central reviewer, and E1 3 times as often (Trimarchi et al., 2017).
“biopsies offer only a snapshot in time of a relatively small sample of tissue”
KDIGO 2025 Clinical Practice Guideline for the Management of IgA Nephropathy and IgA Vasculitis
For that reason the guideline says there is no evidence that choosing treatment by the MEST-C score improves outcomes. The code is one input, read alongside urine protein, eGFR and blood pressure.
How Urine Protein Relates to the IgA Nephropathy Outlook
Urine protein is the lab result KDIGO calls the only validated early marker for guiding treatment. The UK's RaDaR registry followed 887 adults from diagnosis. When protein averaged under 0.44g/g, 78% avoided kidney failure or death for 10 years. When it averaged 1.76g/g or more, only 15% did (Pitcher et al., 2023).
Trial Friend joined 3 sources for this chart. The survival figures are from Table 2 of the UK RaDaR registry study (Pitcher et al., 2023), and the at-risk line is from the KDIGO 2025 guideline. The trial bars are the protein minimums of recruiting US adult trials, read from ClinicalTrials.gov on November 19, 2026. Below 0.5g/g, none of those trial minimums is met.
Those registry figures describe groups, not any one person. RaDaR enrolled only people whose protein was above 0.5 grams a day or whose eGFR was below 60. Its patients were 77% White and 71% male, and its authors say the results may not carry over to other countries (Pitcher et al., 2023).
The paper was published in 2023, before most of today's IgA nephropathy drugs were approved. Its authors concluded that few patients could expect to avoid kidney failure in their lifetime unless kidney function loss stayed at about 1mL/min a year or less.
KDIGO reaches a similar conclusion in its 2025 guideline. It says a person with IgA nephropathy faces a significant lifetime risk of losing kidney function. Even a low risk at 5 years can add up over the decades that follow.
NIDDK's patient page sounds a gentler note. Last reviewed in 2022, it says IgA nephropathy does not get worse over time in many cases, and that about 1 in 5 people develop kidney failure within 10 years of diagnosis. Part of the gap is likely who gets counted, since RaDaR only enrolled people who already had raised protein or reduced kidney function.
The International IgAN Prediction Tool
The International IgAN Prediction Tool turns these measures into a single estimate. It was built and tested on 3,927 adults from Europe, North America, China and Japan. It estimates the 5-year risk of losing half of kidney function or reaching kidney failure (Barbour et al., 2019).
The tool uses eGFR, blood pressure, urine protein, age, the MEST scores and medicines taken at the time of the biopsy. It is free on Calculate by QxMD. KDIGO calls it a valuable way to talk about risk, but says it should not be used to choose a specific treatment and is validated only within 2 years of a biopsy.
How IgA Nephropathy Treatment Starts Under the 2025 KDIGO Guideline
The 2025 KDIGO guideline asks for 2 kinds of treatment to begin at the same time rather than one after the other. One aims at the immune process that makes the harmful IgA, and the other manages kidney damage that has already happened. The guideline expects that second part to be lifelong (KDIGO, 2025).
For the kidney-protecting side, KDIGO recommends an ACE inhibitor or ARB at the highest dose a person tolerates. It also suggests an SGLT2 inhibitor and Filspari (sparsentan) as options, and Filspari takes the place of an ACE inhibitor or ARB rather than being added to one.
The same section pairs those medicines with less than 2 grams of sodium a day, stopping smoking and vaping, and weight control. On the immune side, KDIGO suggests a 9-month course of Nefecon, sold in the United States as Tarpeyo. Where Nefecon is not available, it suggests a reduced-dose steroid course instead.
The guideline does not grade Vanrafia (atrasentan), Fabhalta (iptacopan), Voyxact (sibeprenlimab), Trutakna (atacicept) or Ultomiris (ravulizumab). Its evidence review ran through August 2024, before the main Phase 3 results for these drugs were published.
Trial Friend's IgA nephropathy treatment comparison sets all 7 approved drugs side by side. Each also has a guide to its first 90 days, such as the one for Filspari. Those guides cover the forms, first tests and support line.
KDIGO says enrollment in a clinical trial should always be considered for people with IgA nephropathy.
Is IgA Nephropathy Inherited?
Genes play a part in IgA nephropathy, though it is not passed down in a simple pattern the way some genetic diseases are. A 2023 review estimated its heritability, the share of risk explained by genes, at 40-50% (Xu et al., 2023).
How often IgA nephropathy runs in families varies widely between studies. An Italian series found family clustering in 14% of patients, while an Irish one found it in 1.8% of IgA nephropathy biopsies (Scolari et al., 1999; Fennelly et al., 2018). The KDIGO 2025 guideline makes no recommendation on testing relatives, so that is a question to raise with the nephrologist.
Tracking IgA Nephropathy Through the First Year
KDIGO asks doctors to reassess risk over time instead of relying on the picture at diagnosis. The guideline sets no schedule for adults' lab tests, so how often urine protein and eGFR are rechecked is worked out with the nephrologist.
Some medicines add their own testing. The Filspari label, for example, calls for liver blood tests before starting and every 3 months after that.
Three questions tend to get the most out of an early follow-up visit. What is my urine protein now, and was it a 24-hour collection or a single sample? How fast has my eGFR changed since the biopsy? Which treatments fit my numbers and my plans, including any plans for pregnancy?
Diet, blood pressure, pregnancy and the blood in the urine that can follow a cold are covered in the companion guide, Living With IgA Nephropathy.
Questions People Ask Right After an IgA Nephropathy Diagnosis
Can IgA nephropathy be cured?
No cure exists yet, and the 2025 KDIGO guideline treats IgA nephropathy as a lifelong condition. Its goal for urine protein is under 0.5 grams a day, ideally under 0.3. It also aims to slow kidney function loss to about the pace of normal aging, under 1mL/min a year for most adults.
How long does it take IgA nephropathy to cause kidney failure?
It varies widely with urine protein and kidney function. The UK RaDaR registry enrolled people with raised protein or reduced kidney function. Median kidney survival there was 11.4 years, and the mean age at kidney failure or death was 48 (Pitcher et al., 2023). NIDDK estimates about 1 in 5 people with IgA nephropathy develop kidney failure within 10 years of diagnosis.
Why does KDIGO count 0.5 grams of urine protein a day as at risk?
Studies show real risk of kidney failure below roughly 1 gram a day. A 2026 review of 23 studies with 15,289 patients pooled 9 of them. Protein of 0.5 to 1.0 grams a day at the start carried 1.73 times the risk of poor kidney outcomes compared with protein under 0.5 (Yamaguchi et al., 2026).
How accurate is the International IgAN Prediction Tool?
In its validation study it ranked who would lose kidney function correctly about 8 times in 10, with a C statistic of 0.81 to 0.82 (Barbour et al., 2019). Its authors suggest using it for a 5-year horizon and no more than 7, and 86.7% of the people it was built on were taking an ACE inhibitor or ARB.
Does a T2 score on an IgA nephropathy biopsy mean kidney failure is coming?
No single score decides that, though T2 means more than half of the sampled tissue shows lasting damage to the tubes and the tissue between the filters. The Oxford group found T to be the most consistent predictor of outcome, and KDIGO says there is no evidence that choosing treatment by the score improves outcomes.
Free email alert
Get IgA nephropathy trial and FDA news by email
One email when a new IgA nephropathy trial opens or the FDA acts on a IgA nephropathy treatment. Unsubscribe anytime.
You'll get trial alerts and disease updates for IgA Nephropathy, and you can turn either off anytime. We never share your email. Privacy policy
Trial Friend articles on IgA nephropathy
November 9, 2026 · 13 min readWhat Parents and Caregivers of a Child With IgA Nephropathy Should Know When Every Approved Drug Is Labeled for AdultsNone of the 7 FDA-approved IgA nephropathy drugs is approved for children, yet 6 of them are now in company studies registered to enroll kids. What the first sign usually looks like, how the childhood disease differs from the adult one, what the 2025 IPNA pediatric recommendations say, and which studies take children.
September 29, 2026 · 13 min readAtacicept vs Povetacicept for IgA Nephropathy Before the FDA Decision on November 30thAtacicept and povetacicept block the same 2 immune signals in IgA nephropathy. Atacicept is approved as Trutakna and now has 2-year kidney data. Povetacicept faces an FDA decision on November 30th and would be injected 13 times a year instead of 52. A side-by-side table, the trial results, what an independent review found, what patients told the FDA, and 7 real-world situations.
September 16, 2026 · 10 min read7 Approved Drugs for IgA Nephropathy and What Their Labels Actually PromiseIgA nephropathy went from zero approved drugs to 7 in under 5 years, most recently Ultomiris. Only 3 have proven on their labels that they protect kidney function. The other 4 are approved on a urine protein number and still owe that proof. Here is the difference and why it matters to you.
March 31, 2026 · 8 min readIgA Nephropathy Went From Zero Approved Drugs to 7 in Under 5 Years, and Where Fabhalta FitsIgA nephropathy had no FDA-approved treatment before December 2021 and has 7 today. This guide lists them, explains Fabhalta's 2-year NEJM results showing 49.3% slower kidney function decline than placebo, and puts Biohaven's early BHV-1400 data in context.
Sources
Trial Friend checked this guide against these sources on November 19, 2026. It explains what kidney guidelines, FDA labels and published studies say. It is not medical advice or a reason to start, stop or change a medicine.
- KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney International 2025;108(4S):S1-S71, KDIGO, 2025-10.
- Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of IgAN and IgAV. Kidney International 2025;108:548-554 (Floege J et al.), 2025-10.
- Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney International 2017;91:1014-1021 (Trimarchi H et al.), 2017-03-22.
- The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International 2009;76:546-556 (Roberts IS et al.), 2009-09.
- Long-Term Outcomes in IgA Nephropathy. Clinical Journal of the American Society of Nephrology 2023;18:727-738 (Pitcher D et al.), 2023-04-13.
- Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Internal Medicine 2019;179:942-952 (Barbour SJ et al.), 2019-07-01.
- IgA Nephropathy. National Institute of Diabetes and Digestive and Kidney Diseases, 2022-09.
- Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review. Kidney360 2023;4:1112-1122 (Kiryluk K et al.), 2023-08.
- An Update on the Genetics of IgA Nephropathy. Journal of Clinical Medicine 2024;13:123 (Xu LL et al.), 2023-12.
- Familial clustering of IgA nephropathy: further evidence in an Italian population. American Journal of Kidney Diseases 1999;33:857-865 (Scolari F et al.), 1999-05.
- Clinical Heterogeneity in Familial IgA Nephropathy. Nephron 2018;139:63-69 (Fennelly NK et al.), 2018.
- The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis. Clinical Journal of the American Society of Nephrology 2026;21:615-625 (Yamaguchi Y et al.), 2026-04.
- FILSPARI (sparsentan) prescribing information. Travere Therapeutics, via DailyMed, 2026-04-09.
- Recruiting IgA nephropathy studies with eligibility criteria. ClinicalTrials.gov, National Library of Medicine, 2026-11-19.
